D. P. Chapman and G. S. Perry, Depression as a Major Component of Public Health for Older Adults, Prev Chronic Dis, vol.5, pp.1-9, 2008.

P. W. Gold, R. Machado-vieira, and M. G. Pavlatou, Clinical and Biochemical Manifestations of Depression: Relation to the Neurobiology of Stress, Neural Plast, pp.7-9, 2015.

D. Richards, Clinical Psychology Review Prevalence and clinical course of depression: A review, Clin. Psychol. Rev, vol.31, pp.1117-1125, 2011.

J. Wang, X. Wu, W. Lai, E. Long, X. Zhang et al., Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis, BMJ Open, p.17173, 2017.

R. C. Kessler and E. J. Bromet, The Epidemiology of Depression Across Cultures, Clin. Rev. Educ, vol.317, pp.2114-2122, 2017.

P. Belujon and A. A. Grace, Dopamine System Dysregulation in Major Depressive Disorders, Int. J. Neuropsychopharmacol, vol.20, pp.1036-1046, 2017.

P. R. Albert, C. Benkelfat, P. R. Albert, and L. Descarries, The neurobiology of depression -revisiting the serotonin hypothesis. II Genetic , epigenetic and clinical studies, Philos. Trans. R. Soc. B, vol.368, pp.3-6, 2013.

C. Moret and M. Briley, The importance of norepinephrine in depression, Neuropsychiatr. Dis. Treat, vol.7, pp.9-13, 2011.

P. J. Cowen and M. Browning, What has serotonin to do with depression?, World Psychiatr, vol.14, pp.11-13, 2015.

A. Cipriani, T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder : a systematic review and network meta-analysis, Lancet, vol.391, issue.17, pp.32802-32809, 2018.

G. Gartlehner, G. Wagner, N. Matyas, V. Titscher, J. Greimel et al., Pharmacological and nonpharmacological treatments for major depressive disorder: review of systematic reviews, BMJ Open, vol.7, pp.1-13, 2017.

E. Penn and D. K. Tracy, The drugs don't work? antidepressants and the current and future pharmacological management of depression, Ther. Adv. Psychopharmacol, vol.2, pp.179-188, 2012.

P. K. Gillman, Tricyclic antidepressant pharmacology and therapeutic drug interactions updated, Br. J. Pharmacol, vol.151, pp.737-748, 2007.

D. J. Mckenna, G. H. Towers, and F. Abbott, Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and b-carboline constituents of Ayahuasca, J. Ethnopharmocology, vol.10, pp.195-223, 1984.

J. J. Fortunato, G. Z. Réus, T. R. Kirsch, R. B. Stringari, L. Stertz et al., Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.33, pp.1425-1430, 2009.

P. Heshmati, M. Nasehi, and M. R. Zarrindast, An overview of cognitive aspects of ?carbolines, J. Paramed. Sci, vol.5, pp.99-104, 2014.

R. Cao, W. Peng, Z. Wang, and A. Xu, Beta-Carboline Alkaloids : Biochemical and Pharmacological Functions, Curr. Med. Chem, vol.14, pp.479-500, 2007.

M. C. Niroumand, M. H. Farzaei, and G. Amin, Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review, J. Tradit. Chinese Med, vol.35, pp.30016-30025, 2015.

E. Frecska, P. Bokor, and M. Winkelman, The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization, Front. Pharmacol, vol.7, pp.1-17, 2016.

T. Herraiz, D. González, C. Ancín-azpilicueta, V. J. Arán, and H. Guillén, b-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO), Food Chem. Toxicol, vol.48, pp.839-845, 2010.

M. Moloudizargari, P. Mikaili, S. Aghajanshakeri, M. H. Asghari, and J. Shayegh, Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids, Pharmacogn. Rev, vol.7, pp.199-212, 2019.

T. Herraiz and C. Chaparro, Human monoamine oxidase enzyme inhibition by coffee and b-carbolines norharman and harman isolated from coffee, Life Sci, vol.78, pp.795-802, 2006.

T. Herraiz, Identification and Occurrence of -Carboline Alkaloids in Raisins and Inhibition of Monoamine Oxidase (MAO), J. Agric. Food Chem, vol.55, pp.8534-8540, 2007.

T. Herraiz and C. Chaparro, Human monoamine oxidase is inhibited by tobacco smoke: b-carboline alkaloids act as potent and reversible inhibitors

, Biophys. Res. Commun, vol.326, pp.378-386, 2005.

F. Palhano-fontes, D. Barreto, H. Onias, K. C. Andrade, M. M. Novaes et al.,

M. Silveira, J. Yonamine, F. R. Riba, A. A. Santos, J. C. Silva-junior et al.,

B. Galvão-coelho, D. B. Lobão-soares, and . Araújo, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebocontrolled trial, Psychol. Med, vol.18, pp.4-12, 2019.

M. Uthaug, K. Van-oorsouw, K. P. Kuypers, M. Van-boxtel, N. J. Broers et al., Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution, Psychopharmacology (Berl), vol.235, pp.2979-2989, 2018.

J. J. Fortunato, G. Z. Réus, T. R. Kirsch, R. B. Stringari, G. R. Fries et al., Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: Further evidence of antidepressant properties, Brain Res. Bull, vol.81, pp.491-496, 2010.

R. A. Glennon, M. Dukat, B. Grella, S. Hong, L. Costantino et al., Binding of b-carbolines and related agents at serotonin (5-HT2 and 5-HT 1A), dopamine (D2) and benzodiazepine receptors, Drug Alcohol Depend, vol.60, pp.121-132, 2000.

A. Adell, T. A. Biggs, and R. D. Myers, Action of Harman (l-methyl-P-carboline) on the Brain: Body Temperature and In Viva Efflux of 5-HT from Hippocampus of the Rat, Neuropharmacology, vol.35, pp.1101-1107, 1996.

D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and T. P. Group, Preferred Reporting Items for Systematic Reviews and Meta-Analyses : The PRISMA Statement, Plos Med, vol.6, p.1000097, 2009.

C. R. Hooijmans, M. M. Rovers, R. B. De-vries, M. Leenaars, M. Ritskeshoitinga et al., SYRCLE ' s risk of bias tool for animal studies, BMC Med. Res. Methodol, vol.14, pp.1-9, 2014.

R. G. De-oliveira-júnior, A. F. Christiane-adrielly, J. R. Da-silva-almeida, R. Grougnet, V. Thiéry et al., Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms, Fitoterapia, vol.129, pp.383-400, 2018.

S. K. Al-nuaimi, E. M. Mackenzie, and G. B. Baker, Monoamine Oxidase Inhibitors and Neuroprotection : A Review, Am. J. Ther, vol.448, pp.436-448, 2012.

M. B. Youdim, D. Edmondson, and K. F. Tipton, The therapeutic potential of monoamine oxidase inhibitors, Nat. Rev, vol.7, pp.295-309, 2006.

K. I. Shulman, N. Herrmann, and S. E. Walker, Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression, CNS Drugs, vol.27, pp.789-797, 2013.

T. Herraiz, A. Flores, and L. Fernández, Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants, J. Chromatogr. B, vol.1073, pp.136-144, 2018.

H. Kim, S. O. Sablin, and R. R. Ramsay, Inhibition of Monoamine Oxidase A by b-Carboline Derivatives, Arch. Biochem. Biophys, vol.337, pp.137-142, 1997.

T. May, H. Rommelspacher, and M. Pawlik, Harman Binding Experiments. I: A Reversible and Selective Radioligand for Monoamine Oxidase Subtype A in the CNS of the Rat, J. Neurochem, vol.56, pp.490-499, 1991.

T. May, M. Pawlik, and H. Rommelspacher,

, Harman Binding and Monoamine Oxidase Subtypes A and B Activity in Marmoset and Rat, J. Neurochem, vol.56, pp.500-508, 1991.

A. F. Arriba, J. N. Lizcano, M. D. Balsa, and M. Unzeta, Inhibition of Monoamine Oxidase from Bovine Retina by b-Carbolines, J. Pharm. Pharmacol, vol.46, pp.809-813, 1994.

D. L. Sparks and N. S. Buckholtz, 6-Methoxy-1,2,3,4-tetrahydro-beta-carboline: a specific monoamine oxidase-A inhibitor in CF-1 mouse brain, Neurosci. Lett, vol.20, pp.73-78, 1980.

F. Borsini and A. Meli, Psychopharmacology Is the forced swimming test a suitable model for revealing antidepressant activity ?, Psychopharmacology (Berl), vol.94, pp.147-160, 1988.

A. Can, D. T. Dao, M. Arad, C. E. Terrillion, S. C. Piantadosi et al., The Mouse Forced Swim Test, J. Vis. Exp, vol.59, pp.4-8, 2012.

R. Yankelevitch-yahav, M. Franko, A. Huly, and R. Doron, The Forced Swim Test as a Model of Depressive-like Behavior, J. Vis. Exp, vol.97, pp.1-7, 2015.

P. Willner, Neurobiology of Stress The chronic mild stress ( CMS ) model of depression: History , evaluation and usage, Neurobiol. Stress, vol.6, pp.78-93, 2017.

P. Willner, Neurobiology of Stress Reliability of the chronic mild stress model of depression: A user survey, Neurobiol. Stress, vol.6, pp.68-77, 2017.

J. J. Fortunato, G. Z. Reus, T. R. Kirsch, R. B. Stringari, G. R. Fries et al., Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus, J. Neural Transm, pp.1131-1137, 2010.

M. F. Festing, Design and Statistical Methods in Studies Using Animal Models of Development, ILAR J, vol.47, pp.5-14, 2006.

J. A. Hirst, J. Howick, J. K. Aronson, N. Roberts, R. Perera et al., The Need for Randomization in Animal Trials: An Overview of Systematic Reviews, PLoS One, vol.9, p.98856, 2014.

P. J. Karanicolas, F. Farrokhyar, and M. Bhandari, Blinding: Who, what, when, why, how?, Can. J. Surg, vol.53, pp.345-348, 2010.

J. E. De-aguilar-nascimento, Fundamental steps in experimental design for animal studies, Acta Cirúrgica Bras, vol.20, pp.2-8, 2005.

T. Denayer, T. Stöhr, and M. Van-roy, Animal models in translational medicine: Validation and prediction, New Horizons Transl. Med, vol.2, pp.5-11, 2014.

C. Belzung, Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects ?, Neuropsychopharmacology, vol.39, pp.1041-1051, 2014.

R. Machado-vieira, Tracking the impact of translational research in psychiatry: state of the art and perspectives, J. Transl. Med, vol.10, p.1, 2012.

W. M. Mcisaac, D. Taylor, K. E. Walker, and B. T. Ho, 6-Methoxy-1,2,3,4-tetrahydro-bcarboline, a serotonin elevator, J. Neurochem, vol.19, pp.1203-1206, 1972.

J. Samard?i?, D. ?. Strac, M. Obradovi?, D. Opri?, and D. I. Obradovi?, DMCM, a benzodiazepine site inverse agonist, improves active avoidance and motivation in the rat, Behav. Brain Res, vol.235, pp.195-199, 2012.

Y. Claustre, L. Rouquier, C. Desvignes, M. Leonetti, N. Aubin et al., Effects of the vasopressin (V1b) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat, Neuroscience, vol.141, pp.1481-1488, 2006.

F. Aricioglu and H. Altunbas, Harmane induces anxiolysis and antidepressant-like effects in rats, Ann. N. Y. Acad. Sci, vol.1009, pp.196-201, 2003.

F. Aricioglu, G. Arkan, C. Kandemir, S. Sirvanci, C. Ozkartal et al., Harmane suppresses microglial neuroinflammatory response and induce antidepressant-like effect in rats, Eur. Psychiatry, vol.415, pp.366-404, 2017.

D. Farzin and N. Mansouri, Antidepressant-like effect of harmane and other bcarbolines in the mouse forced swim test, Eur. Neuropsychopharmacol, vol.16, pp.324-328, 2006.

K. L. Smith, G. K. Ford, D. S. Jessop, and D. P. Finn, Behavioural , neurochemical and neuroendocrine effects of the endogenous ?-carboline harmane in fear-conditioned rats, J. Psychopharmacol, vol.27, pp.162-170, 2013.

F. Liu, J. Wu, Y. Gong, P. Wang, L. Zhu et al., Harmine produces antidepressant-like effects via restoration of astrocytic functions, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.79, pp.258-267, 2017.

R. Pahkla, J. Harro, and L. Rago, Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests, Pharmacol. Res, vol.34, pp.73-78, 1996.

R. Pahkla, L. Rago, J. J. Callaway, and M. M. Airaksinen, Binding of Pinoline on the 5-Hydroxytryptamine Transporter: Competitive Interaction with [3H] Citalopram, Pharmacol. Toxicol, vol.80, pp.122-126, 1996.

K. R. Methuku, X. Li, R. Cerne, S. D. Gleason, J. M. Schkeryantz et al., An antidepressant-related pharmacological signature for positive allosteric modulators of ?2/3-containing GABAA receptors, Pharmacol. Biochem. Behav, vol.170, pp.9-13, 2018.

J. Moncrieff, Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by highperformance liquid chromatography with fluorimetric detection, J. Chromatogr. B Biomed. Sci. Appl, vol.496, pp.269-278, 1989.

M. J. Schouten and J. Bruinvels, Endogenously Formed Norharman

, Platelet Rich Plasma Obtained From Porphyric Rats, Pharmacol. Toxicol, vol.24, pp.1219-1223, 1986.

H. Rommelspacher, T. May, and R. Susilo, B-carbolines and tetrahydroisoquinolines: Detection and Function in Mammals, Planta Med, vol.57, pp.85-92, 1991.

S. Iuliana, R. Aro, B. Kiss, M. Manto, and P. Duez, The Role of ?-Carboline Alkaloids in the Pathogenesis of Essential Tremor, Cerebellum, vol.15, pp.276-284, 2015.

H. Guille and V. J. Ara, Oxidative Metabolism of the Bioactive and Naturally Occurring Carboline Alkaloids, Norharman and Harman, by Human Cytochrome P450 Enzymes, Chem. Res. Toxicol, vol.21, pp.2172-2180, 2008.

O. Beck and K. F. Faull, Concentrations of the enantiomers of 5-hydroxymethtryptolne implications for in uivo biosynthesis in mammalian urine, Biochem. Pharmacol, vol.435, pp.2636-2639, 2011.

D. W. Shoemaker, J. T. Cummins, T. G. Bidder, H. G. Boetgger, and M. Evans, Identification of Harman in the Rat Arcuate Nucleus, Naunyn. Schmiedebergs. Arch. Pharmacol, vol.230, pp.227-230, 1980.

T. R. Bosin, S. Borg, and K. F. Faull, Harman in Rat Brain, Lung and Human CSF: Effect of Alcohol Consumption, Alcohol, vol.5, pp.505-511, 1989.

H. Abu, M. D. Lalies, D. J. Nutt, and A. L. Hudson, Harmane: An atypical neurotransmitter ?, Neurosci. Lett, vol.590, pp.1-5, 2015.

J. A. Fuentes and V. G. Longo, An investigation on the central effects of harmine, harmaline and related B-carbolines, Neuropharmacology, vol.10, pp.15-23, 1971.

F. Aricioglu, O. Yillar, E. Korcegez, and K. Berkman, Effect of Harmane on the Convulsive Threshold in Epilepsy Models in Mice, Ann. N. Y. Acad. Sci, vol.1009, pp.190-195, 2003.

I. Komsuoglu, T. Utkan, S. Selcen, A. Hudson, and F. Aricioglu, Effect of harmane, an endogenous ?-carboline, on learning and memory in rats, Pharmacol. Biochem. Behav, vol.103, pp.666-671, 2013.

T. L. Sourkes, Rational hope" in the early treatment of Parkinson's disease, Can, J. Physiol. Pharmacol, vol.77, pp.62-63, 1999.

Y. Guan, E. D. Louis, and W. Zheng, Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats, J. Toxicol. Environ. Health, vol.64, pp.645-660, 2001.

D. H. Kim, Y. Y. Jang, E. S. Han, and C. S. Lee, Protective effect of harmaline and harmalol against dopamine-and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes , and viability loss of PC12 cells, Eur. J. Neurosci, vol.13, pp.1861-1872, 2001.

D. J. Moura, M. Franc, A. Pe, M. Boeira, and J. Saffi, Antioxidant properties of bcarboline alkaloids are related to their antimutagenic and antigenotoxic activities, Mutagenesis, vol.22, pp.293-302, 2007.

A. Astulla, A. K. Zaima, A. Y. Matsuno, Y. Hirasawa, A. W. Ekasari et al., Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities, J. Nat. Med, vol.62, pp.470-472, 2008.

H. Waki, K. W. Park, N. Mitro, L. Pei, R. Damoiseaux et al., The Small Molecule Harmine Is an Antidiabetic Cell-Type-Specific Regulator of PPAR g Expression, Cell Metab, vol.5, pp.357-370, 2007.

J. Im, Y. Jin, J. Lee, J. Yu, X. Han et al., Antiplatelet activity of ?-carboline alkaloids from Perganum harmala: A possible mechanism through inhibiting PLC ? 2 phosphorylation, Vascul. Pharmacol, vol.50, pp.147-152, 2009.

F. Osório, R. F. Sanches, L. R. Macedo, R. G. Santos, P. M. Oliveira et al., Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report, Rev. Bras. Psiquiatr, vol.37, pp.13-20, 2015.

R. F. Sanches, F. D. Osório, R. G. Santos, L. R. Macedo, J. P. Maia-de-oliveira et al., Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression, J. Clin. Psychopharmacol, vol.36, pp.77-81, 2016.

E. D. Freis, Mental Depression in Hypertensive Patients Treated for Long Periods with Large Doses of Reserpine, N. Engl. J. Med, vol.251, pp.1006-1008, 1954.

E. Jesulola, P. Micalos, and I. J. Baguley, Understanding the pathophysiology of depression : From monoamines to the neurogenesis hypothesis model -are we there yet ?, Behav. Brain Res, vol.341, pp.79-90, 2018.

M. Hamon and P. Blier, Monoamine neurocircuitry in depression and strategies for new treatments, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.45, pp.54-63, 2013.

C. Belzung, P. Willner, and P. Philippot, Depression: from psychopathology to pathophysiology, Curr. Opin. Neurobiol, vol.30, 2015.

J. Dean and M. Keshavan, The neurobiology of depression: An integrated view, Asian J. Psychiatr, vol.27, pp.101-111, 2018.

J. S. Goldberg, C. E. Jr, and D. A. Pollard, Revisiting the Monoamine Hypothesis of Depression: A New Perspective, Perspect. Medicin. Chem, pp.1-8, 2014.

Z. Fi?ar, Drugs related to monoamine oxidase activity, Prog. Neuropsychopharmacol. Biol. Psychiatry, vol.69, pp.112-124, 2016.

S. Corbineau, M. Breton, J. Mialet-perez, and J. , Costemale-lacoste, Major depression and heart failure: Interest of monoamine oxidase inhibitors, Int. J. Cardiol, vol.247, pp.1-6, 2017.

B. P. Guiard and G. D. Giovanni, Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?, Front. Pharmacol, vol.6, pp.1-17, 2015.

P. Celada, M. V. Puig, M. Amargós-bosch, A. Adell, and F. Artigas, The therapeutic role of 5-HT1A and 5-HT2A receptors in depression, J. Psychiatry Neurosci, vol.29, pp.252-265, 2004.

E. J. Huang and L. Reichardt, Neurotrophins: Roles in Neuronal Development and Function, Annu. Rev. Neurosci, vol.24, pp.677-736, 2001.

E. Castrén, V. Voikar, and T. Rantamaki, Role of neurotrophic factors in depression, Curr. Opin. Pharmacol, vol.7, pp.18-21, 2007.

R. S. Duman and L. M. Monteggia, A Neurotrophic Model for Stress-Related Mood Disorders, Biol. Psychiatry, vol.59, pp.1116-1127, 2006.

L. M. Monteggia, M. Barrot, C. M. Powell, O. Berton, V. Galanis et al., Essential role of brain-derived neurotrophic factor in adult hippocampal function, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.10827-10832, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00142913

R. Gary and Y. Barde, Physiology of neurotrophins, Annu. Rev. Neurosci, vol.19, pp.289-317, 1996.

V. Krishnan and E. J. Nestler, The molecular neurobiology of depression, Nature, vol.455, pp.894-902, 2008.

F. Karege, G. Vaudan, M. Schwald, N. Perroud, and R. L. Harpe, Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs, Mol. Brain Res, vol.136, pp.29-37, 2005.

M. E. Kozisek, D. Middlemas, and D. B. Bylund, Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies, Pharmacol. Ther, vol.117, pp.30-51, 2008.

M. Leventopoulos, D. Rüedi-bettschen, I. Knuesel, J. Feldon, C. R. Pryce et al., Opacka-juffry, Long-term effects of early life deprivation on brain glia in Fischer rats, Brain Res, vol.1142, pp.119-126, 2007.

S. Olivera-bravo, A. Fernández, M. N. Sarlabós, J. C. Rosillo, G. Casanova et al., Neonatal Astrocyte Damage Is Sufficient to Trigger Progressive Striatal Degeneration in a Rat Model of, PLoS One, vol.6, pp.1-10, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00685064

B. Schreiner, E. Romanelli, and F. Heppner, Astrocyte Depletion Impairs Redox Homeostasis and Triggers Neuronal Loss in the Adult CNS Report Astrocyte Depletion Impairs Redox Homeostasis and Triggers Neuronal Loss in the Adult CNS, Cell Rep, vol.12, pp.1377-1384, 2015.